Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Europe United Kingdom Cost Effectiveness

England’s Innovative Medicines Fund: Opportunities & Risks

  • News

Executive Summary

England’s Innovative Medicines Fund could make the UK a more attractive launch market following Brexit, but companies must also consider the risks of the fund.

You may also be interested in...



England Launches Innovative Medicines Fund

The new financing mechanism promises faster access to new treatments, but some industry concerns remain unresolved.

Premature Filings Add To EU Regulatory Resource Challenge

The pharmaceutical legislation overhaul offers some solutions to the problem of immature applications.

Early Advice Could Help Companies Maintain EU Conditional Marketing Authorizations

The number of conditional marketing authorization non-renewals could increase.

Table

View full table

Topics

Tags:
Europe United Kingdom Cost Effectiveness
Latest Headlines

Pink Sheet Podcast: CAR-T Malignancy Reports, Background Music In DTC Ads, New No. 2 At US FDA

‘Vast Amount Of Valuable Input’ Leads Australia To Extend HTA Review

French Regulator At Odds With EMA Over Safety Restrictions For Pseudoephedrine

US FDA’s Patient-Focused Drug Development Program Meetings Evolve With Technology Focus

See All
UsernamePublicRestriction

Register

PS146487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By